Alligator Bioscience Granted First U.S. Patent for Neo-X-Prime™ Bispecific Antibody ATOR-4066 for Cancer Treatment

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. US 11,873,348 covering ATOR-4066, a Neo-X-Prime™ next generation bispecific antibody targeting CD40 and CEACAM5, in the treatment of cancer.

The patent, titled ”Novel peptides”, provides ATOR-4066 with protection regarding methods of treating cancer and/or a tumor using a bispecific antibody comprising the complementarity-determining regions (CDRs) of the ATOR-4066 molecule.

The patent is the first patent of the ATOR-4066 intellectual property portfolio which is expected to strengthen as more patents are filed and granted. Its accelerated application was part of the Cancer Immunotherapy Pilot program, which provided a fast-track review for cancer immunotherapy-related patent applications in the U.S.

"By simultaneously targeting CD40 and a tumor associated antigen, ATOR-4066 has demonstrated superior anti-tumor immunity, and we see medical opportunities for this first-in-class preclinical asset in , multiple cancer indications, targeting both cold and hot tumor types " said Søren Bregenholt, CEO of Alligator Bioscience. "The granting of this patent is an important step in the ongoing development of ATOR-4066 and we place great emphasis on the protection of our intellectual property as a key component of our drug development program and our overall business strategy."

ATOR-4066 was developed by Alligator's proprietary Neo-X-Prime™ platform that generates bispecific conditional antibody agonists able to significantly boost dendritic cells and T-cell activation by connecting them to tumor debris.

Updated 2024-01-16